- Home
- PSF vs DBVT Comparison
PSF vs DBVT Comparison
Compare PSF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- DBVT
- Stock Information
- Founded
- PSF 2010
- DBVT 2002
- Country
- PSF United States
- DBVT France
- Employees
- PSF N/A
- DBVT N/A
- Industry
- PSF Investment Managers
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSF Finance
- DBVT Health Care
- Exchange
- PSF Nasdaq
- DBVT Nasdaq
- Market Cap
- PSF 245.5M
- DBVT 260.5M
- IPO Year
- PSF N/A
- DBVT N/A
- Fundamental
- Price
- PSF $20.61
- DBVT $9.87
- Analyst Decision
- PSF
- DBVT Buy
- Analyst Count
- PSF 0
- DBVT 4
- Target Price
- PSF N/A
- DBVT $14.81
- AVG Volume (30 Days)
- PSF 25.0K
- DBVT 33.1K
- Earning Date
- PSF 01-01-0001
- DBVT 11-05-2025
- Dividend Yield
- PSF 7.69%
- DBVT N/A
- EPS Growth
- PSF N/A
- DBVT N/A
- EPS
- PSF N/A
- DBVT N/A
- Revenue
- PSF N/A
- DBVT $3,800,000.00
- Revenue This Year
- PSF N/A
- DBVT $1,743.46
- Revenue Next Year
- PSF N/A
- DBVT $1,045.66
- P/E Ratio
- PSF N/A
- DBVT N/A
- Revenue Growth
- PSF N/A
- DBVT N/A
- 52 Week Low
- PSF $16.00
- DBVT $2.21
- 52 Week High
- PSF $20.19
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- PSF 60.87
- DBVT 55.30
- Support Level
- PSF $20.32
- DBVT $8.70
- Resistance Level
- PSF $20.60
- DBVT $10.19
- Average True Range (ATR)
- PSF 0.14
- DBVT 0.51
- MACD
- PSF 0.01
- DBVT 0.05
- Stochastic Oscillator
- PSF 100.00
- DBVT 71.25
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.